Treatment selection and influencing factors for chronic lymphocytic leukemia: a physician survey in Japan
Although many Japanese hematologists select their treatment based on clinical evidence, variations exist in treatment strategies, possibly associated with hematologists' experience and interest in CLL. These findings underscore the importance of further promoting evidence-based treatments to ensure that all physicians can make informed decisions. Future research should explore additional factors that influence CLL treatment decisions.
Authors
- Yoshinori Tanizawa (ORCID: https://orcid.org/0000-0002-5014-2483)
- Satoshi Osaga (ORCID: https://orcid.org/0000-0003-4459-2469)
- Tomoko Terasawa
- Shori Takaoka (ORCID: https://orcid.org/0009-0008-3495-6963)
- Masaomi Tajimi (ORCID: https://orcid.org/0000-0001-5815-377X)
- Junichiro Yuda (ORCID: https://orcid.org/0000-0002-4908-1636)
- Chaochen Wang (ORCID: https://orcid.org/0000-0001-5533-1497)
- Moemi Miura (ORCID: https://orcid.org/0009-0007-8632-9294)
Institutions
- Eli Lilly (Japan) (JP)
- National Cancer Center Hospital East (JP)
- ShinEtsu Chemical (Japan) (JP)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2024-10-21
- DOI
- https://doi.org/10.1007/s10147-024-02645-6
- Citations
- 1
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.44
Funders
- Eli Lilly and Company
- Eli Lilly Japan